Where mid-infrared spectroscopy meets medicine

30 Jan

Loïc Maurel joins Diafir as Strategic Advisor

Loïc Maurel is Medical Doctor and cumulates 30 years of senior management experience in tier-one pharmaceutical, biotech and Diagnostics companies. As the CEO of the Diaxonhit Group (now Eurobio Scientific), Loïc inspired and led the transformation of a pure biotech company, into a full fledge commercial IVD company, following the acquisition of Ingen BioSciences and […]

10 Nov

Press Release: DIAFIR announces the acceptance of an abstract at The Liver Meeting Digital Experience™ 2020

RENNES, FRANCE— November 04, 2020 DIAFIR, a medical technology company focused on the development, manufacture and sale of innovative diagnostic solutions, today announced that an abstract has been selected for poster presentation during the upcoming The Liver Meeting Digital Experience™ 2020, organized by the American Association for the Study of Liver Disease (AASLD) on November […]


DIAFIR has been incepted in 2011 by a world-renowned team of researchers from Rennes 1 University, France.

DIAFIR has developed the SPID™ platform, a breakthrough proprietary device for patient screening triage. SPID™ analyses the entire metabolic signature spectrum of patient’s blood serum, within minutes, using mid-infrared spectroscopy.

Thanks to its platform, DIAFIR aims to develop and bring to market its revolutionary serum test NASHMIR® for NASH detection.

Our goal is to help save lives through early detection while being minimally invasive to the patient.


  • DIAFIR’s vision is to become the standard of care in the way people are routinely checked for NASH (early detection).
  • DIAFIR’s method is easy to implement and at a low cost, currently targeting the obese patients as the first choice for NASH detection.
  • Our proprietary platform SPID™ can be applied on other types of diseases (as a start we are focused on NASH and infectious arthropathies).